Genmab
Genmab’s CLL drug gets negative opinion from EMA committee
June 24, 2016Medical Communications, Research and Development, Sales and Marketing Arzerra, CHMP, CLL, EMA, Genmab, blood cancer
Genmab A/S (Nasdaq Copenhagen: GEN) said its drug Arzerra (ofatumumab) received a negative opinion by the Committee for Medicinal Products …
Phase III trials to start in Novartis/Genmab multiple sclerosis collaboration
June 2, 2016Research and Development Arzerra, Genmab, Novartis, multiple sclerosis, ofatumumab, phase III
Genmab (NASDAQ: GEN) has announced that its collaboration partner, Novartis, is set to initiate Phase III trials for ofatumumab in …
Darzalex meets endpoint in late-stage multiple myeloma trial
May 19, 2016Research and Development Genmab, Janssen, daratumumab, darzalex, dexamethasone, lenalidomide, phase 3, phase III, trial
Genmab has announced that positive results from a Phase III trial evaluating Darzalex (daratumumab), which is being developed in partnership …
Janssen and Genmab sued for patent infringement in US
April 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Genmab, Janssen, darzalex, morphosys, patent infringement
German biotech company, Morphosys, is suing Janssen and Genmab for alleged patent infringement in their oncology drug, Darzalex (daratumumab).
Darzalex to be trialled in combination with atezolizumab in multiple myeloma and solid tumours
March 22, 2016Research and Development Genentech, Genmab, Janssen, Roche, atezolizumab, clnical trials, multiple myeloma, phase ib, solid tumours, tumour
Phase Ib clinical studies are set to begin, which will evaluate Darzalex (daratumumab) in combination with atezolizumab in a solid …
Novartis seeks expanded Arzerra use in US
March 11, 2016Research and Development Arzerra, CLL, FDA, Genmab, Novartis
Novartis has submitted a supplemental Biologics License Application (sBLA) to the US FDA for the use of Arzerra (ofatumumab) in …
Genmab Darzalex success triggers second milestone payment
March 10, 2016Research and Development, Sales and Marketing Genmab, Janssen, daratumumab, darzalex, follicular lymphoma
Genmab says it has reached a $5 million milestone in its daratumumab collaboration with Janssen as a result of success …
Arzerra approved by US FDA for leukaemia
January 20, 2016Research and Development, Sales and Marketing Afrezza, CLL, FDA, Genmab, Novartis, chronic lymphocytic leukaemia, ofatumumab, sBLA, supplementary biologics license application
The FDA has signed-off a supplemental Biologics License Application (sBLA), meaning Arzerra is approved for extended treatment of patients who …
Genmab pulls plug on Phase III Arzerra trial
November 24, 2015Manufacturing and Production, Research and Development Arzerra, Genmab, non-Hodgkin's lymphoma, non-Hodgkin’s lymphoma, ofatumumab, phase III, phase III failure
Genmab has stopped a Phase III study of its CD20-directed monoclonal antibody Arzerra, after it was shown to be unlikely …
EMA gets first line Arzerra submission
October 7, 2013Sales and Marketing Arzerra, GSK, Genmab, blood cancer
GlaxoSmithKline and Genmab have submitted their blood cancer drug Arzerra to the European Medicines Agency (EMA) in a first line …
J&J buys into Genmab cancer drug
August 31, 2012Sales and Marketing Cancer, Genmab, Janssen Cilag, Janssen-Cilag, Johnson & Johnson, multiple myeloma
Danish biotech company Genmab has sold the worldwide rights for one of its cancer drugs to Johnson & Johnson-owned Janssen …
GSK settles cancer patent dispute
March 28, 2012Research and Development, Sales and Marketing GSK, Genmab, Roche, ofatumumab, patents
GlaxoSmithKline has settled a long-running patent dispute over its cancer treatment ofatumumab. The US patents, which relate to recombinant antibody …
GSK switches to subcutaneous route for antibody
September 16, 2010Research and Development Arzerra, Genmab, GlaxoSmithKline, ofatumumab
GlaxoSmithKline says it will switch development of a new antibody treatment to a subcutaneous injection, to make it more commercially …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
